133184-80-2

Basic information

• Product Name: N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE
• Synonyms: 2-(1-Pyrrolidinyl)-5-(trifluoromethyl)aniline;ART-CHEM-BB B025580;ASISCHEM Z50533;BUTTPARK 44\09-70;2-PYRROLIDIN-1-YL-5-TRIFLUOROMETHYL-PHENYLAMINE;AKOS BB-8559;AKOS B025580;3-AMINO-4-(1-PYRROLIDINO)BENZOTRIFLUORIDE
• CAS NO: 133184-80-2
• Molecular Formula: C₁₁H₁₃F₃N₂
• Molecular Weight: 230.23
• Mol File: 133184-80-2.mol

Chemical Properties

• Melting Point: 33 °C
• Boiling Point: 315.4 °C at 760 mmHg
• Flash Point: 144.5 °C
• Appearance: /
• Density: 1.28 g/cm³
• Vapor Pressure: 0.00022mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C
• PKA: 5.51±0.40(Predicted)
• CAS DataBase Reference: N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE(133184-80-2)
• EPA Substance Registry System: N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE(133184-80-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 133184-80-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE is used as a building block for the synthesis of various pharmaceutical drugs and molecules. Its unique structure allows it to be a key component in the development of new medications, contributing to the advancement of medical treatments.
Used in Research and Development:
In the field of research, N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE is used as a research tool for studying chemical and biological processes. Its properties and interactions with other compounds provide valuable insights into the mechanisms of various biological systems and the development of new therapeutic approaches.
Used in Potential Pharmacological Applications:
N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PYRROLIDINE has been studied for its potential pharmacological properties, indicating its use as a candidate for the treatment of various medical conditions. Its specific role in these applications is still under investigation, but its unique chemical structure offers promising avenues for therapeutic development.

InChI:InChI=1/C9H6ClFO2/c10-8-5-7(11)3-1-6(8)2-4-9(12)13/h1-5H,(H,12,13)/b4-2+

Upstream product

• 40832-82-4 1-(2-nitro-4-(trifluoromethyl)phenyl)pyrrolidine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 

Downstream Products

• 1309358-82-4 1-phenyl-N-[2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl]cyclopropane-carboxamide 

Relevant articles and documents

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Access to Polycyclic Indole-3,4-Fused Nine-Membered Ring via Cascade 1,6-Hydride Transfer/Cyclization

A cascade aldimine condensation/1,6-hydride transfer/Mannich-type cyclization of indole-derived phenylenediamine with aldehydes was developed for one-step construction of a polycyclic indole-3,4-fused skeleton. Aldehyde serves as a key to start the whole process, including 1,6-hydride transfer enabled δ-C(sp3)-H activation of the secondary amine. The challenges of construction of medium-sized rings are addressed via hydride transfer chemistry.

Tert-amino effect-promoted rearrangement of aryl isothiocyanate: A versatile approach to benzimidazothiazepines and benzimidazothioethers

A general and practical approach to benzimidazothiazepine and benzimidazothioether derivatives via an intramolecular nucleophilic addition/ring expansion rearrangement of aryl isothiocyanates promoted by the tert-amino effect has been developed. This reaction is catalyzed by low-cost camphorsulfonic acid and tolerates a broad substrate scope with complete atom economy. Structurally intriguing benzimidazothiazepine and benzimidazothioether products could be easily obtained by a simple operation in good to excellent yield (up to 98%).

Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs)

The serine/arginine-rich protein kinases (SRPKs) have frequently been found with altered activity in a number of cancers, suggesting they could serve as potential therapeutic targets in oncology. Here we describe the synthesis of a series of twenty-two tr

METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhi